EXPRESSION OF THE TYPE 1 TYROSINE KINASE GROWTH FACTOR RECEPTORS EGF RECEPTOR, c-erbB2 AND c-erbB3 IN BLADDER CANCER
β Scribed by RAJKUMAR, THANGARAJAN; STAMP, GORDON W. H.; PANDHA, HARDEV S.; WAXMAN, JONATHAN; GULLICK, WILLIAM J.
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 704 KB
- Volume
- 179
- Category
- Article
- ISSN
- 0022-3417
No coin nor oath required. For personal study only.
β¦ Synopsis
Expression of the c-erbB3 protein was determined in transitional cell carcinoma of the bladder by immunohistochemistry. Strong membrane staining was observed in 10 per cent of cases (7/70) and cytoplasmic and membrane overexpression in 20 per cent (14/70). Overexpression of the epidermal growth factor (EGF) receptor (36 per cent, 25/70) and c-erbB2 proteins (9 per cent 6/70) was determined in the same series of cases. c-erbB3 overexpression was positively correlated with EGF receptor expression (P<0-025) but appeared to be inversely associated with c-erbB2 overexpression. KEY WORDS+pidermal growth factor receptor; c-erbB2; c-erbB3; bladder cancer; oncogenes
π SIMILAR VOLUMES
## It is well established that activation of cellular genes may trigger uncontrolled cell growth and cancer development. Previous reports suggest that the epidermal growth factor receptor (EGFr), c-erbB2/neu and int-2, fibroblast growth factor-3, may be implicated in the development of benign pros
BACKGROUND. This study evaluated the prognostic significance of immunohistochemical staining for cathepsin D, epidermal growth factor receptor (EGFR). and c-erbB-2 in patients with early cervical squamous cell carcinoma. ## METHODS. This retrospective analysis comprised 132 patients, all subjecte
## Abstract ## BACKGROUND: Lung cancer is the leading cause of cancer death in the world. The objective of this study was to investigate the expression of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in patients with nonsmall cell lung cancer (NSCLC) and its correlation
ful in predicting the clinical outcome of transitional cell carcinoma of the bladder, they also create uncertainty. Immunohistochemical staining for p53, MIB-1, epi-